Article Details
Retrieved on: 2024-02-05 20:45:04
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses NXC-201 clinical trials targeting AL amyloidosis—a proteinopathy linked to protein misfolding, causing organ damage which is categorically a form of amyloidosis and associated with neurological disorders and pathology.
Article found on: www.marketwatch.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here